Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...
Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...
Blood-based liquid biopsy tests for colorectal cancer (CRC) are in development and may soon hit the market, expanding potential options for patients who refuse traditional colonoscopy. But would they ...
On May 27, the American Cancer Society published updated screening guidelines for colorectal cancer, officially adding Guardant Health’s FDA-approved Shield blood test to its list of approved ...
cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
BRISBANE, Calif., May 27, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the American Cancer ...
Please provide your email address to receive an email when new articles are posted on . CMS will use newly defined criteria to qualify noninvasive biomarker CRC screening tests for coverage. Concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results